These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 34538007)

  • 21. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy.
    Yu L; Huang K; Liao Y; Wang L; Sethi G; Ma Z
    Cell Prolif; 2024 Aug; 57(8):e13644. PubMed ID: 38594879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
    Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI
    J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.
    Germanà E; Pepe L; Pizzimenti C; Ballato M; Pierconti F; Tuccari G; Ieni A; Giuffrè G; Fadda G; Fiorentino V; Martini M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
    De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
    Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
    Fang XN; Fu LW
    Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
    Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
    Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
    Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
    Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Biomarkers for Melanoma Immunotherapy.
    Twitty CG; Huppert LA; Daud AI
    Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.